Orphan Drugs

Drugs and biologics intended to treat rare and neglected diseases have been given the name, ‘ Orphan Drugs’  by the Orphan drug designation program for the safe and effective treatment and proper diagnosis or prevention of rare diseases that affect 1:20000 people but are not expected to recover the costs of developing and marketing a treatment drug. In addition to orphan drugs, there are orphan vaccines for disease control and the prevention of spread of contagious rare diseases. Vaccines are expensive to develop for a small number of rare infectious diseases and hence only eight vaccines have been registered with the orphan status. Some of the Orphan drugs are, Rituximab, Bortezomib, Sorafenib, Sacrosidase, Clofezimine, and Nilotinib, etc. The nature of Orphan Drugs can create a difference in the amount of safety information for approval needed for limited number of patients in clinical trials and quality of the clinical trials.

  • Rituxan
  • Soliris
  • Tasigna
  • Avonex
  • Yervoy
  • Rebif
  • Jakavi
  • Kyprolis
  • Novoseven
  • Revlimid
  • Sprycel

Related Conference of Orphan Drugs

May 10-11, 2021

4th Global Experts Meeting on Infectious Diseases

Singapore City, Singapore
May 27-28, 2021

7th Rare Diseases and Orphan Drugs

Vienna, Austria
July 19-20, 2021

13th Global Infections Conference

Tokyo, Japan
September 06-07, 2021

11th World Congress on Rare Diseases and Orphan Drugs

Berlin, Germany
October 21-22, 2021

International Conference on Tropical Diseases and Cure

Zurich, Switzerland
November 22-23, 2021

3rd World Congress on Advancements in Tuberculosis and Lung Diseases

Singapore City, Singapore
February 07-08, 2022

9th International Congress on Infectious Diseases

Aberdeen, UK

Orphan Drugs Conference Speakers

Recommended Sessions

Related Journals

Are you interested in